2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-106447
    Losulazine 72141-57-2 98%
    Losulazine is an antihypertensive agent acting by a sympatholytic mechanism. Losulazine's hypotensive activity depends on the presence of an intact, functional sympathetic nervous system.
    Losulazine
  • HY-106471
    Pildralazine 64000-73-3 98%
    Pildralazine (Propyldazine) is a hydralazinelike antihypertensive vasodilator containing a free hydrazine group. Pildralazine is orally active, has no significant carcinogenicity in mice model.
    Pildralazine
  • HY-106476
    Primidolol 67227-55-8 98%
    Primidolol (UK-11443), derived from Parmotrema perlatum, possesses antibacterial and antioxidant activities. Primidolol is also an orally active α/β Adrenergic Receptor blocker with antihypertensive activity. Primidolol can be used in research related to infections and cardiovascular diseases.
    Primidolol
  • HY-106499
    Sulfinalol 66264-77-5 98%
    Sulfinalol is an orally active β-adrenoceptor antagonist with direct vasodilator activity.
    Sulfinalol
  • HY-106523
    Nipradolol 81486-22-8 98%
    Nipradolol (KT-210; K-351) is a potent blocker of alpha-1-adrenergic receptors. Nipradolol inhibits the increase of intraocular pressure (IOP) in an albino rabbit model induced by Phenylephrine (HY-B0769). Nipradolo suppresses the noradrenaline (NA)-induced muscles contraction, also exhibits vasodilator activity on the dog coronary artery.
    Nipradolol
  • HY-106554
    Trimazosin 35795-16-5 98%
    Trimazosin is an orally active, quinazoline derivative which is structurally related to prazosin. Trimazosin shows hypotensive effect by selectively block α1-adrenoceptors.
    Trimazosin
  • HY-106559
    Sorbinicate 6184-06-1 98%
    Sorbinicate, a derivative of nicotinic acid, exerts a favourable influence on blood rheology and platelet function.
    Sorbinicate
  • HY-10655A
    Palosuran hydrochloride 2469274-58-4 98.67%
    Palosuran hydrochloride (ACT-058362 hydrochloride) is a potent, selective, and orally active antagonist of urotensin II receptor, with an IC50 of 3.6 nM for CHO cell membranes expressing human recombinant receptors. Palosuran hydrochloride can improves pancreatic and renal function in diabetic rats.
    Palosuran hydrochloride
  • HY-106561
    Tioclomarol 22619-35-8 98%
    Tioclomarol, a coumarin anticoagulant, is a vitamin K antagonist.
    Tioclomarol
  • HY-106565
    Meproscillarin 33396-37-1 98%
    Meproscillarin (Methylproscillaridin) is a glycoside. Meproscillarin can be used for research of heart failure.
    Meproscillarin
  • HY-106580
    Plafibride 63394-05-8 98%
    Plafibride (ITA 104) is an orally active hypolipemic, platelet aggregation inhibitor.
    Plafibride
  • HY-10664R
    SB-611812 (Standard) 345892-71-9 98%
    SB-611812 (Standard) is the analytical standard of SB-611812. This product is intended for research and analytical applications. SB-611812 is a urotensin II receptor (UTR) antagonist with the potential in the research of cardiovascular disease.
    SB-611812 (Standard)
  • HY-106688
    Alinidine 33178-86-8 98%
    Alinidine (St-567) is a specific bradycardic agent. Alinidine reduces the slope of the diastolic depolarization in sinoatrial tissue and Purkinje fibers. Alinidine shows antiischemic and antiarrhythmic effects.
    Alinidine
  • HY-106761
    Oxodipine 90729-41-2 98%
    Oxodipine, a dihydropyridine-type calcium antagonist, inhibits KCl-induced aortic contraction in rabbits and reduces cardiac force in less potent rat ventricular test-paper contractions. In rat cultured neonatal ventricular myocytes, Oxodipine reduces L-type Ca currents (I) with an IC50 of 0.24 μM, and against T-type Ca currents (I) with an IC50 of 0.41 μM. Oxodipine causes constipation in mice and gingival hyperplasia in dogs.
    Oxodipine
  • HY-106816
    Ceronapril 111223-26-8 98%
    Ceronapril (SQ 29852) is a potent and orally active angiotensin converting enzyme (ACE) inhibitor with an IC50 of 36 nM.
    Ceronapril
  • HY-106832
    Vatanidipine 116308-55-5 98%
    Vatanidipine (Watanidipine) is an orally active dihydropyridine (DHP)-type calcium channel blocker and a useful antihypertensive agent. Vatanidipine shows vasodilatory effects and also suppresses noradrenaline release from sympathetic nerve endings.
    Vatanidipine
  • HY-106855
    Almokalant 123955-10-2 98%
    Almokalant is a class III antiarrhythmic agent, acts as a potassium channel blocker, and inhibits a specific component (Ikr) of the time-dependent delayed rectifier K+ current.
    Almokalant
  • HY-106895
    Antiarrhythmic agent-1 136081-07-7 98%
    Antiarrhythmic agent-1 (example I) is an antiarrhythmic agent and an IKr potassium channel blocker (IC50<1 μM).
    Antiarrhythmic agent-1
  • HY-106902
    F-1394 162490-89-3 98%
    F-1394 is an orally active acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor that inhibits dietary cholesterol absorption in mice. F-1394 can be used in cardiovascular disease research.
    F-1394
  • HY-106904
    Nexopamil 136033-49-3 98%
    Nexopamil is a calcium antagonist of Ca2+ channel, 5HT2, 5HT1A, 5HT1C and dopamine D2 receptors. Nexopamil exhibits vasodilatory, cardioprotective, and platelet aggregation inhibiting effects. Nexopamil can be used for researches of stable or unstable angina and possibly of peripheral arterial occlusive disease.
    Nexopamil
Cat. No. Product Name / Synonyms Application Reactivity